FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B Turnover 20.45%
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+2.26%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
-$221M
Cap. Flow
-$84.5M
Cap. Flow %
-3.86%
Top 10 Hldgs %
70.17%
Holding
54
New
4
Increased
10
Reduced
8
Closed
7
Avg Time Held
1.6 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.7 years

Top Buys

Rank Stock Value
1
MAZE icon
Maze Therapeutics
MAZE
+$49.7M
2
DYN icon
Dyne Therapeutics
DYN
+$20.6M
3
RNAM
Avidity Biosciences
RNAM
+$16.4M
4
ZLAB icon
Zai Lab
ZLAB
+$10.8M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$10.6M

Top Sells

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$66.1M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$33.9M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$21.7M
4
ANAB icon
AnaptysBio
ANAB
+$20.8M
5
KRYS icon
Krystal Biotech
KRYS
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.79%
2 Miscellaneous 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NAMS icon
1
NewAmsterdam Pharma
NAMS
$2.39B
$330M 15.08%
16,116,418
+200,000
+1% +$4.45M
2022 Q4
9 quarters
MIRM icon
2
Mirum Pharmaceuticals
MIRM
$5.19B
$306M 13.99%
6,795,121
+224,729
+3% +$10.6M
2022 Q1
12 quarters
VRNA
3
DELISTED
Verona Pharma
VRNA
$220M 10.03%
3,457,850
+73,900
+2% +$4.42M
2022 Q3
10 quarters
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.32B
$137M 6.28%
8,785,284
– –
2022 Q1
12 quarters
BBIO icon
5
BridgeBio Pharma
BBIO
$12.7B
$131M 6%
3,800,457
– –
2023 Q1
8 quarters
KRYS icon
6
Krystal Biotech
KRYS
$9.79B
$124M 5.67%
688,460
-100,000
-13% -$16.8M
2022 Q1
12 quarters
IRON icon
7
Disc Medicine
IRON
$2.14B
$87.1M 3.98%
1,754,834
– –
2023 Q2
7 quarters
TARS icon
8
Tarsus Pharmaceuticals
TARS
$3.38B
$71.8M 3.28%
1,397,527
-190,000
-12% -$9.39M
2022 Q1
12 quarters
TRVI icon
9
Trevi Therapeutics
TRVI
$1.72B
$64.5M 2.95%
10,259,409
-405,365
-4% -$1.93M
2022 Q2
11 quarters
PHAT icon
10
Phathom Pharmaceuticals
PHAT
$599M
$63.4M 2.9%
10,109,279
– –
2022 Q1
12 quarters
KALV icon
11
DELISTED
KalVista Pharmaceuticals
KALV
$56.4M 2.58%
4,887,867
– –
2022 Q1
12 quarters
MAZE icon
12
Maze Therapeutics
MAZE
$1.46B
$45.5M 2.08%
+4,129,001
New +$49.7M
2025 Q1
0 quarters
MBX icon
13
MBX Biosciences
MBX
$2.35B
$44.2M 2.02%
5,985,347
– –
2024 Q3
2 quarters
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$5.97B
$36M 1.64%
678,760
-1,191,048
-64% -$66.1M
2022 Q3
10 quarters
SLNO icon
15
DELISTED
Soleno Therapeutics
SLNO
$35.7M 1.63%
499,159
-200,000
-29% -$9.74M
2023 Q3
6 quarters
RVMD icon
16
Revolution Medicines
RVMD
$41.5B
$35.3M 1.61%
997,455
– –
2023 Q1
8 quarters
SVRA icon
17
Savara
SVRA
$978M
$31.8M 1.45%
11,462,301
+2,801,922
+32% +$7.74M
2023 Q3
6 quarters
AGIO icon
18
Agios Pharmaceuticals
AGIO
$1.85B
$31.3M 1.43%
1,069,854
+100
+0% +$3.32K
2023 Q3
6 quarters
ERAS icon
19
Erasca
ERAS
$5.14B
$30.9M 1.41%
22,575,851
+3,184,164
+16% +$5.46M
2024 Q2
3 quarters
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$1.47B
$23.9M 1.09%
658,715
– –
2024 Q2
3 quarters
ASND icon
21
Ascendis Pharma A/S
ASND
$14.9B
$20.8M 0.95%
133,333
– –
2024 Q3
2 quarters
PCVX icon
22
Vaxcyte
PCVX
$10.6B
$20.4M 0.93%
539,405
– –
2022 Q1
12 quarters
ALKS icon
23
Alkermes
ALKS
$6.56B
$19.8M 0.91%
601,129
– –
2024 Q3
2 quarters
PVLA icon
24
Palvella Therapeutics
PVLA
$1.77B
$19.3M 0.88%
690,012
+36,120
+6% +$696K
2024 Q3
2 quarters
CGON icon
25
CG Oncology
CGON
$5.48B
$18.9M 0.86%
770,000
– –
2024 Q1
4 quarters
1
2 3

Similar funds

BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
MR
Munich Reinsurance Munich $4.57B AUM 28.39% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2025 Portfolio in Review

As of Q1 2025, Frazier Life Sciences Management held 54 positions worth $2.19B, down 9.2% from $2.41B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Frazier Life Sciences Management withdrew a net $84.5M in Q1 2025, closing 7 positions and reducing 8 holdings. Its most notable exit was Edgewise Therapeutics, an estimated $33.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Frazier Life Sciences Management opened a new position in Maze Therapeutics worth $45.5M.

  • Frazier Life Sciences Management's largest Q1 2025 buy was Maze Therapeutics: 4,129,001 shares worth $45.5M.
  • Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q1 2025, an estimated $10.6M increase.
  • Frazier Life Sciences Management's biggest Q1 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $66.1M.
  • Frazier Life Sciences Management fully exited Edgewise Therapeutics in Q1 2025, selling an estimated $33.9M.
  • Frazier Life Sciences Management's ten largest holdings make up 70% of its $2.19B portfolio in Q1 2025.
  • Frazier Life Sciences Management opened 4 new positions and closed 7 in Q1 2025.
  • Frazier Life Sciences Management's portfolio value fell 9.2% quarter-over-quarter to $2.19B.

Based on Frazier Life Sciences Management's 13F filing for Q1 2025, filed 15 May 2025.